Takase K - Search Results

1

Calreticulin and integrin alpha dissociation induces anti-inflammatory programming in animal models of inflammatory bowel disease.

Ohkuro M, Kim JD, Kuboi Y, Hayashi Y, Mizukami H, Kobayashi-Kuramochi H, Muramoto K, Shirato M, Michikawa-Tanaka F, Moriya J, Kozaki T, Takase K, Chiba K, Agarwala KL, Kimura T, Kotake M, Kawahara T, Yoneda N, Hirota S, Azuma H, Ozasa-Komura N, Ohashi Y, Muratani M, Kimura K, Hishinuma I, Fukamizu A. Ohkuro M, et al. Among authors: takase k. Nat Commun. 2018 May 17;9(1):1982. doi: 10.1038/s41467-018-04420-4. Nat Commun. 2018. PMID: 29773794 Free PMC article.

2

Hsp90 inhibitor geldanamycin attenuates the cytotoxicity of sunitinib in cardiomyocytes via inhibition of the autophagy pathway.

Kimura T, Uesugi M, Takase K, Miyamoto N, Sawada K. Kimura T, et al. Among authors: takase k. Toxicol Appl Pharmacol. 2017 Aug 15;329:282-292. doi: 10.1016/j.taap.2017.06.015. Epub 2017 Jun 15. Toxicol Appl Pharmacol. 2017. PMID: 28624441

3

Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.

Kimura T, Kato Y, Ozawa Y, Kodama K, Ito J, Ichikawa K, Yamada K, Hori Y, Tabata K, Takase K, Matsui J, Funahashi Y, Nomoto K. Kimura T, et al. Among authors: takase k. Cancer Sci. 2018 Dec;109(12):3993-4002. doi: 10.1111/cas.13806. Epub 2018 Nov 16. Cancer Sci. 2018. PMID: 30447042 Free PMC article.

4

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.

Okamoto K, Kodama K, Takase K, Sugi NH, Yamamoto Y, Iwata M, Tsuruoka A. Okamoto K, et al. Among authors: takase k. Cancer Lett. 2013 Oct 28;340(1):97-103. doi: 10.1016/j.canlet.2013.07.007. Epub 2013 Jul 12. Cancer Lett. 2013. PMID: 23856031 Free article.

5

Targeted delivery of anticancer drugs to tumor vessels by use of liposomes modified with a peptide identified by phage biopanning with human endothelial progenitor cells.

Fukuta T, Asai T, Kiyokawa Y, Nakada T, Bessyo-Hirashima K, Fukaya N, Hyodo K, Takase K, Kikuchi H, Oku N. Fukuta T, et al. Among authors: takase k. Int J Pharm. 2017 May 30;524(1-2):364-372. doi: 10.1016/j.ijpharm.2017.03.059. Epub 2017 Mar 27. Int J Pharm. 2017. PMID: 28359814

6

Antitumor and Antiangiogenic Activities of Lenvatinib in Mouse Xenograft Models of Vascular Endothelial Growth Factor-Induced Hypervascular Human Hepatocellular Carcinoma.

Adachi Y, Matsuki M, Watanabe H, Takase K, Kodama K, Matsui J, Funahashi Y, Nomoto K. Adachi Y, et al. Among authors: takase k. Cancer Invest. 2019;37(4-5):185-198. doi: 10.1080/07357907.2019.1601209. Epub 2019 Apr 22. Cancer Invest. 2019. PMID: 31006280

7

Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.

Narita Y, Okamoto K, Kawada MI, Takase K, Minoshima Y, Kodama K, Iwata M, Miyamoto N, Sawada K. Narita Y, et al. Among authors: takase k. Mol Cancer Ther. 2014 Apr;13(4):823-32. doi: 10.1158/1535-7163.MCT-13-0667. Epub 2014 Jan 21. Mol Cancer Ther. 2014. PMID: 24448821

8

A novel truncated glucagon-like peptide 2 (GLP-2) as a tool for analyzing GLP-2 receptor agonists.

Yamazaki K, Kagaya T, Watanabe M, Terauchi H, Iida D, Fukumoto H, Suzuki S, Arai T, Aoki M, Takase K, Seiki T, Tsukahara K, Nagakawa J. Yamazaki K, et al. Among authors: takase k. Biomed Res. 2013 Jun;34(3):129-36. doi: 10.2220/biomedres.34.129. Biomed Res. 2013. PMID: 23782746 Free article.

9

Ago-allosteric modulators of human glucagon-like peptide 2 receptor.

Yamazaki K, Terauchi H, Iida D, Fukumoto H, Suzuki S, Kagaya T, Aoki M, Koyama K, Seiki T, Takase K, Watanabe M, Arai T, Tsukahara K, Nagakawa J. Yamazaki K, et al. Among authors: takase k. Bioorg Med Chem Lett. 2012 Oct 1;22(19):6126-35. doi: 10.1016/j.bmcl.2012.08.026. Epub 2012 Aug 14. Bioorg Med Chem Lett. 2012. PMID: 22944117

10

Identification and optimisation of a series of tetrahydrobenzotriazoles as metabotropic glutamate receptor 5-selective positive allosteric modulators that improve performance in a preclinical model of cognition.

Ellard JM, Madin A, Philps O, Hopkin M, Henderson S, Birch L, O'Connor D, Arai T, Takase K, Morgan L, Reynolds D, Talma S, Howley E, Powney B, Payne AH, Hall A, Gartlon JE, Dawson LA, Castro L, Atkinson PJ. Ellard JM, et al. Among authors: takase k. Bioorg Med Chem Lett. 2015 Dec 15;25(24):5792-6. doi: 10.1016/j.bmcl.2015.10.050. Epub 2015 Oct 17. Bioorg Med Chem Lett. 2015. PMID: 26531152

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,109 results

Search Page

Filters